Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Equity (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Equity for 6 consecutive years, with 0.81% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 45.0% year-over-year to 0.81%, compared with a TTM value of 0.81% through Sep 2025, down 45.0%, and an annual FY2024 reading of 0.39%, down 4.0% over the prior year.
  • Return on Equity was 0.81% for Q3 2025 at Barinthus Biotherapeutics, down from 0.64% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.05% in Q1 2021 and bottomed at 0.81% in Q3 2025.
  • Average Return on Equity over 5 years is 0.25%, with a median of 0.24% recorded in 2023.
  • The sharpest move saw Return on Equity grew 11bps in 2022, then tumbled -45bps in 2025.
  • Year by year, Return on Equity stood at 0.09% in 2021, then soared by 123bps to 0.02% in 2022, then plummeted by -1976bps to 0.38% in 2023, then fell by -10bps to 0.42% in 2024, then crashed by -92bps to 0.81% in 2025.
  • Business Quant data shows Return on Equity for BRNS at 0.81% in Q3 2025, 0.64% in Q2 2025, and 0.53% in Q1 2025.